We are developing a non-invasive retinal amyloid detection tool for early diagnosis of Alzheimer’s, stroke risk, and concussions. Using AI-powered retinal imaging and sound-based signal processing, it offers a real-time, cost-effective alternative to PET scans. With a B2B model, revenue streams include device sales, diagnostics subscriptions, and licensing. Currently raising $2M for R&D, regulatory approvals, and market entry.